DrugPatentWatch Database Preview
EXSERVAN Drug Profile
Email this page to a colleague
» See Plans and PricingWhich patents cover Exservan, and what generic alternatives are available?
Exservan is a drug marketed by Aquestive Therap and is included in one NDA.
The generic ingredient in EXSERVAN is riluzole. There are nine drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the riluzole profile page.
US ANDA Litigation and Generic Entry Outlook for Exservan
A generic version of EXSERVAN was approved as riluzole by IMPAX LABS on January 29th, 2003.
Summary for EXSERVAN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | EXSERVAN at DailyMed |
Pharmacology for EXSERVAN
| Drug Class | Benzothiazole |
US Patents and Regulatory Information for EXSERVAN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aquestive Therap | EXSERVAN | riluzole | FILM;ORAL | 212640-001 | Nov 22, 2019 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
